PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castration‐resistance prostate cancer patients treated with docetaxel. (16th February 2021)
- Record Type:
- Journal Article
- Title:
- PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castration‐resistance prostate cancer patients treated with docetaxel. (16th February 2021)
- Main Title:
- PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castration‐resistance prostate cancer patients treated with docetaxel
- Authors:
- Shi, Xinyu
Pei, Xinqi
Fan, Junjie
Liu, Tianjie
Zhang, Dize
Yang, Tao
Wu, Kaijie
He, Dalin
Li, Lei - Abstract:
- Abstract: Prostate‐specific antigen nadir (nPSA) and time to nPSA (TTN) have been proved to be associated with the prognosis of prostate cancer. In this study, we explored the prognosis effect of nPSA and TTN during initial androgen deprivation therapy (ADT) in patients with metastatic castration‐resistant prostate cancer (mCRPC) after treatment with docetaxel‐based chemotherapy. The data of 153 mCRPC patients received docetaxel followed by ADT were retrospectively reviewed. Multivariate Cox regression analysis demonstrated that TTN (overall survival (OS): Hazard ratio [HR] 0.096, 95% confidence interval [CI] 0.045–0.206, p < .001; progression‐free survival (PFS): HR 0.128, 95% CI 0.078–0.211, p < .001) and nPSA (OS: HR 2.849, 95% CI 1.318–6.157, p = .008; PFS: HR 1.573, 95% CI 1.008–2.454, p = .046) acted as independent predictors of chemotherapy prognosis. Kaplan‐Meier analysis showed that patients with nPSA ≥ 0.2 ng/ml or TTN < 6.5 months had shorter OS and PFS. These results suggest that TTN and nPSA during ADT can affect the prognosis of docetaxel‐based chemotherapy prognosis post‐castration resistance in patients with mCRPC, and higher nPSA and shorter TTN lead to poor chemotherapy prognosis. What is more, TTN has a greater impact during ADT on the prognosis of chemotherapy than nPSA.
- Is Part Of:
- Andrologia. Volume 53:Number 4(2021)
- Journal:
- Andrologia
- Issue:
- Volume 53:Number 4(2021)
- Issue Display:
- Volume 53, Issue 4 (2021)
- Year:
- 2021
- Volume:
- 53
- Issue:
- 4
- Issue Sort Value:
- 2021-0053-0004-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2021-02-16
- Subjects:
- androgen deprivation therapy -- docetaxel -- metastatic castration‐resistant prostate cancer -- PSA nadir -- time to PSA nadir
Andrology -- Periodicals
Infertility, Male -- Periodicals
616.69 - Journal URLs:
- https://onlinelibrary.wiley.com/journal/14390272 ↗
https://www.hindawi.com/journals/and/ ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/and.13916 ↗
- Languages:
- English
- ISSNs:
- 0303-4569
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0900.443000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 16858.xml